Navigation Links
New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
Date:7/27/2011

SAN DIEGO, July 27, 2011 /PRNewswire/ -- bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today study results published in the next issue of the Journal of Molecular Diagnostics related to the clinical validity and the clinical utility of CancerTYPE ID®, its 92-gene molecular classification test to aid in the determination of the origin of a tumor. The company also announced Medicare reimbursement coverage.

The study, Performance and Clinical Evaluation of the 92-Gene Real-time PCR Assay for Tumor Classification, demonstrates that CancerTYPE ID classifies 30 main tumor types and 54 histological subtypes, covering over 95% of all solid tumors. A database of 2206 specimens with a median of 62 samples per tumor type allowed for the increase in tissue coverage. The 92-gene classification algorithm demonstrated sensitivities of 87% for the 30 main tumor types and 85% for the 54 histological subtypes.  

"Our study featured a 300 consecutive clinical case series in which CancerTYPE ID classified 22 types and 36 different subtypes, which included several rare tumors. This real-world clinical finding shows the importance of having a comprehensive scope of reportable tumor types to resolve differential diagnosis, to avoid the risk of misclassification and for overall clinical applicability," said Richard Ding, Chief Executive Officer of bioTheranostics. "This study provides more evidence that CancerTYPE ID is establishing a new standard in the emerging field of molecular cancer classifiers."

Additional highlights from the study showed that CancerTYPE ID can discriminate among tumor types that pose diagnostic dilemmas including neuroendocrine subtypes, squamous carcinomas (head and neck vs. lung), tumors present in the ovary (ovarian mucinous vs. GI tumor), and gynecological tumors (cervical vs. ovarian). "Thought leaders in the field and our physician customers have provided us valuable input regarding essential tumor types for molecular classifiers. We are pleased that CancerTYPE ID can address their diagnostic challenges," said Mark Erlander, PhD, Chief Scientific Officer of bioTheranostics. "Target therapies for metastatic cancers require precise knowledge of both tissue origin and underlying pathways. Our product provides critical information as a part of cancer management."

bioTheranostics also announced that CancerTYPE ID is now a covered benefit for Medicare Part B patients following a coverage determination by Medicare's administrative contractor Palmetto GBA. "This coverage decision was based on a review of the evidence supporting the analytical validity, clinical validity and clinical utility of CancerTYPE ID, making it one of the few molecular cancer tests supported by a Medicare coverage decision," Ding said. "It's another milestone in the history of bioTheranostics as we continue to improve existing products and bring additional high medical value products to market."

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community to support targeted disease management. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index(SM), which provides risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and CancerTYPE ID, a cancer classification assay that provides molecular classification of cancers with indeterminate, uncertain, or differential diagnoses to aid in the determination of the tumor site of origin. For more information call Client Services at 1-877-886-6739 or visit www.bioTheranostics.com.

For more information, including quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/162271.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached euro 1.223 billion with 85% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

bioTheranostics Contacts
Tim Schofield
Tel: +1 858 587 5890
tim.schofield@biotheranostics.com

bioMerieux Contact
Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14
media@biomerieux.com


'/>"/>
SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
3. As New Data Wave Begins, a Gene Study in One Disease Discovers Mutations in an Unrelated Disease
4. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
5. Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds
6. Diesel fumes pose risk to heart as well as lungs, study shows
7. Narrowest bridges of gold are also the strongest, study finds
8. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
9. University of Dayton Study Overturns 250-Year-Old Belief About Effects of Age, Repeated Injury on Tissue Regeneration
10. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
11. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... 8, 2016  Partnering to fuel Philadelphia,s ... Partners of Southeastern Pennsylvania (" ... company of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") ... for a $6 million funding initiative over a four ... Responding to a burgeoning economic vitality in digital ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... from its phase I/II dose escalation and expansion clinical trial for its lead ... Vienna, Austria. The purpose of the trial was to determine the safety, antitumor ...
Breaking Biology Technology:
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of ... the most crucial aspects of recovery so we need to do it well. Inadequate ... including heart problems, high blood pressure, stroke, diabetes, and even cancer. Maybe ... find a Christmas present that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):